Evaluating Past Site Performance: A Key to Smarter Clinical Trial Feasibility

Introduction: Why Historical Site Performance Matters

In the competitive landscape of clinical trials, choosing the right sites can make or break a study. One of the most predictive indicators of future success is a site’s historical performance in prior trials. Regulators like the FDA and EMA expect sponsors and CROs to use past performance as part of risk-based site selection under ICH E6(R2) guidelines.

Evaluating site performance isn’t simply about how fast a site can enroll. It includes understanding past enrollment trends, protocol deviation rates, audit findings, data quality issues, and patient retention patterns. This article provides a detailed methodology for assessing historical site performance as part of a robust feasibility process, supported by real-world examples and performance dashboards.

Key Performance Indicators (KPIs) for Site History Evaluation

To evaluate a site’s past performance, sponsors should examine a mix of quantitative and qualitative KPIs. These include:

• Actual vs. projected enrollment rates
• Screen failure ratios and dropout rates
• Frequency and severity of protocol deviations
• Query resolution timelines and data quality metrics
• Audit findings (internal, sponsor, and regulatory)
• Inspection outcomes (e.g., FDA 483s, Warning Letters)
• Timeliness of regulatory and EC submissions
• Monitoring burden (e.g., number of follow-ups required)

These metrics should be reviewed for at least 3–5 previous trials, ideally within the same therapeutic area and trial phase.

Sources of Historical Site Performance Data

Collecting past performance data requires a blend of internal systems, external databases, and direct site engagement. Typical sources include:

• CTMS (Clinical Trial Management System): Site visit logs, enrollment data, deviation reports
• EDC Systems: Query logs, data entry timelines, SDV delays
• Monitoring Reports: CRA visit notes, risk indicators
• Trial Master File (TMF): Inspection reports, CAPAs, and audit summaries
• Regulatory Databases: Publicly available inspection databases like [FDA 483 Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/fda-inspection-database)
• WHO ICTRP or [ClinicalTrials.gov](https://clinicaltrials.gov): Used to identify prior studies at the site or by the PI

Sample Performance Scorecard Template

A standardized scorecard helps quantify site performance for comparative analysis.

Such tools allow sponsors to adopt objective, data-driven site selection methodologies.

Case Study: Impact of Historical Performance on Site Choice

In a global oncology trial, Sponsor X was selecting 40 sites across Europe and Asia. Site X1 had responded quickly to feasibility and had solid infrastructure. However, their CTMS record showed:

• 8 major protocol deviations in the last study
• 2 instances of delayed AE reporting
• 5 subject dropouts within the first 4 weeks

Despite strong initial feasibility responses, these historical indicators led the sponsor to deselect the site. Another site with moderate infrastructure but better historical KPIs was chosen instead, reducing overall trial risk.

How to Score and Benchmark Sites

Organizations can develop internal scoring systems based on historical metrics. A basic example includes:

• Enrollment performance: 30 points
• Protocol compliance: 30 points
• Data quality: 20 points
• Inspection/audit history: 20 points

Sites scoring above 80 may be pre-qualified. Those under 60 should be considered only with additional oversight or justification.

Integrating Performance Data into Feasibility Systems

To make site history actionable, integration into planning systems is essential:

• Link CTMS and feasibility dashboards for real-time performance scoring
• Use machine learning to predict high-risk sites based on historical patterns
• Tag underperforming sites with audit flags or CAPA requirements
• Centralize all prior audit and deviation data into the site master profile

Organizations using integrated platforms report faster site selection, improved regulatory compliance, and better patient retention.

Regulatory Expectations for Documenting Site Selection

Per ICH E6(R2), sponsors must “select qualified investigators and sites” and provide documentation to justify their selection. Key expectations include:

• Documented rationale for site inclusion or exclusion
• Evidence of performance metrics and monitoring trends
• Identification and mitigation of prior compliance issues
• Storage of evaluations in the TMF for inspection purposes

EMA inspectors, for example, may request justification for selecting a site with prior inspection findings or underperformance, especially if not mitigated by CAPAs.

Best Practices for Historical Site Review

• Review minimum 3 prior trials within the last 5 years
• Include PI-specific metrics as well as site-wide data
• Engage QA to review audit and CAPA history
• Cross-check with public databases (e.g., FDA 483s, EU CTR)
• Use scorecards to support selection meetings and approvals
• Archive all scoring and rationale documents in the TMF

Conclusion

Evaluating a site’s past performance is a critical component of modern, risk-based clinical trial feasibility. It ensures that decisions are informed, justified, and aligned with regulatory expectations. Sponsors and CROs that adopt structured performance reviews—integrated with feasibility workflows and planning systems—can reduce trial risks, enhance subject safety, and accelerate startup timelines. As trials become more complex and globalized, historical data will remain a core strategic asset in clinical operations planning.

Emerging Trends in Regulatory Audit Findings for Global Clinical Trials

Introduction: The Changing Landscape of Global Inspections

Over the past decade, clinical trial inspections have evolved significantly as regulatory agencies adapt to new challenges, technologies, and trial designs. The FDA, EMA, MHRA, and PMDA have emphasized transparency, data integrity, and patient safety as core priorities. More recently, the COVID-19 pandemic and the rise of decentralized clinical trials (DCTs) have reshaped inspection practices, resulting in new patterns of audit findings.

Recent inspection reports reveal consistent trends: increasing focus on data integrity in digital systems, remote monitoring practices, CRO oversight, risk-based monitoring, and transparency of trial disclosures. Sponsors must understand these evolving trends to remain inspection-ready in a rapidly changing regulatory environment.

Trend 1: Greater Scrutiny of Data Integrity

Data integrity continues to be the most frequently cited issue in global inspections. Agencies highlight the ALCOA+ principles—data must be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available. Recent trends show heightened scrutiny of electronic data capture (EDC) systems and audit trails:

• ✅ Regulators increasingly cite missing or unreliable audit trails in EDC platforms.
• ✅ Non-validated systems remain a recurring finding, particularly in emerging markets.
• ✅ Inadequate backup and archiving systems contribute to compliance gaps.

For example, EMA inspectors in 2022 cited sponsors for failure to validate decentralized trial platforms used during the pandemic. These findings highlight that while digital solutions enhance efficiency, they also require rigorous validation and oversight.

Trend 2: Protocol Deviations and Risk-Based Monitoring

Another prominent trend involves protocol deviations, especially in multicenter and decentralized trials. Regulators note an increase in unreported or inadequately documented deviations, often linked to insufficient risk-based monitoring. Findings include:

• ➤ Enrollment of ineligible patients due to decentralized recruitment processes.
• ➤ Remote monitoring failing to detect deviations in real time.
• ➤ Inconsistent adherence to protocol amendments across sites.

These issues reflect both operational challenges and systemic oversight gaps. Regulators expect sponsors to design monitoring plans that balance decentralization with robust oversight.

Trend 3: Safety Reporting Deficiencies

Despite repeated regulatory emphasis, deficiencies in serious adverse event (SAE) and SUSAR reporting remain prevalent. Recent audits highlight:

• ✅ Delays in SAE reporting due to fragmented communication channels in global trials.
• ✅ Incomplete safety narratives submitted in regulatory reports.
• ✅ Lack of reconciliation between safety databases and clinical trial data.

These findings demonstrate that sponsors must invest in integrated safety management platforms to streamline reporting and maintain compliance with both FDA and EMA timelines.

Trend 4: Transparency and Disclosure Obligations

Regulators are placing increasing emphasis on trial transparency, requiring sponsors to register and disclose results in global databases. Findings frequently cite late or incomplete postings in registries such as ClinicalTrials.gov and the EU Clinical Trials Register. Trends include:

• ➤ Delays in disclosing negative results, undermining transparency.
• ➤ Inconsistencies between registered protocols and actual trial conduct.
• ➤ Failure to update registry information after protocol amendments.

Regulatory authorities now cross-reference registry data during inspections, increasing the likelihood of findings linked to transparency failures.

Trend 5: Oversight of CROs and Subcontractors

Global trials increasingly rely on CROs and subcontractors, but sponsor oversight remains a common audit deficiency. Findings include:

• ✅ Sponsors failing to document performance oversight of CROs.
• ✅ Inconsistent SOPs across subcontractors in different regions.
• ✅ Lack of governance structures for vendor management.

These findings reinforce the regulatory expectation that sponsors cannot delegate accountability, even if operational tasks are outsourced.

Case Study: Remote Inspection Findings Post-Pandemic

In 2021, an FDA remote inspection of a Phase III oncology trial identified systemic issues in remote monitoring. Investigators noted delayed detection of protocol deviations and inconsistent SAE reporting due to inadequate remote systems. CAPA implementation required upgrading monitoring technology, retraining site staff, and creating centralized dashboards to harmonize reporting across all sites. This case illustrates the growing importance of validated digital systems in regulatory compliance.

Root Causes of Recent Trends

Root cause analysis across multiple inspection reports indicates recurring themes:

• ➤ Rapid adoption of decentralized and digital technologies without adequate validation.
• ➤ Fragmented sponsor oversight of CROs and subcontractors.
• ➤ Inadequate staff training on evolving regulations and trial designs.
• ➤ Lack of harmonized global SOPs for multinational trials.

These systemic gaps reflect the challenges of modern trial complexity, requiring sponsors to rethink compliance frameworks and adopt forward-looking risk management strategies.

CAPA Strategies to Address Emerging Trends

To address these recent findings, sponsors should adopt targeted CAPA approaches, including:

1. Immediate corrective actions such as updating registry postings and reconciling safety databases.
2. Root cause analysis of monitoring and oversight gaps.
3. Preventive measures including validated decentralized platforms, global SOP harmonization, and enhanced CRO oversight.
4. Verification through internal audits, mock inspections, and follow-up monitoring.

CAPA must not only fix deficiencies but also anticipate future risks as trial designs and technologies evolve.

Conclusion: Preparing for the Future of Inspections

Recent trends in global clinical trial audit findings reflect an evolving regulatory landscape shaped by digitalization, decentralization, and increasing transparency demands. Data integrity, protocol deviations, safety reporting, CRO oversight, and disclosure obligations remain high-priority inspection areas. Sponsors that adapt their compliance systems to these trends will not only avoid findings but also build resilience in an increasingly complex regulatory environment.

Inspection readiness is no longer about addressing historical deficiencies but about anticipating emerging risks. By investing in validated digital systems, harmonized global processes, and proactive oversight, sponsors and sites can strengthen regulatory compliance and safeguard trial credibility worldwide.